Cargando…

Risk of Covid-19 with renin-angiotensin-aldosterone system medications

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232911/ http://dx.doi.org/10.1007/s40278-020-78440-2

Ejemplares similares

The renin angiotensin aldosterone system and COVID-19
por: Alsufyani, Hadeel A., et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
por: Reynolds, Harmony R., et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
por: Jarcho, John A., et al.
Publicado: (2020)

Renin-angiotensin-aldosterone system and COVID-19 infection
por: Alexandre, Joachim, et al.
Publicado: (2020)

Covid-19, hypokalaemia and the renin-angiotensin-aldosterone system
por: Mandal, Amit.K.J., et al.
Publicado: (2021)

Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19
por: Williams, Bryan, et al.
Publicado: (2020)

Antagonizing the renin–angiotensin–aldosterone system in the era of COVID-19
por: Sarzani, Riccardo, et al.
Publicado: (2020)

COVID‐19 and renin angiotensin aldosterone system: Pathogenesis and therapy
por: Babajani, Fatemeh, et al.
Publicado: (2021)

Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19
por: Matsuzawa, Yasushi, et al.
Publicado: (2022)

Renin-angiotensin-aldosterone system inhibitors and the COVID-19 epidemic
por: Silva-Cardoso, José, et al.
Publicado: (2022)

Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
por: Tsampasian, Vasiliki, et al.
Publicado: (2022)

The Influence of Long Term Hydrochlorothiazide Administration on the Relationship between Renin-Angiotensin-Aldosterone System Activity and Plasma Glucose in Patients with Hypertension
por: Xiao, Xu, et al.
Publicado: (2013)

The effect of eplerenone on the renin‐angiotensin‐aldosterone system of rats with thyroid dysfunction
por: Dizaye, Kawa, et al.
Publicado: (2019)

Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review
por: Ferrari, Filipe, et al.
Publicado: (2021)

Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
por: Loader, Jordan, et al.
Publicado: (2021)

Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
por: Kang, Si-Hyuck, et al.
Publicado: (2021)

Emergence and evolution of the renin–angiotensin–aldosterone system
por: Fournier, David, et al.
Publicado: (2012)

Beyond the Circulating Renin–Angiotensin Aldosterone System
por: De Mello, Walmor C.
Publicado: (2014)

The renin‐angiotensin‐aldosterone system and its suppression
por: Ames, Marisa K., et al.
Publicado: (2019)

Cardiovascular Risk Reduction with Renin-Angiotensin Aldosterone System Blockade
por: Houston Miller, Nancy
Publicado: (2010)

Fallacies in medical practice: Renin-angiotensin-aldosterone system inhibition and COVID-19 as a Paradigm
por: Triposkiadis, Filippos, et al.
Publicado: (2021)

COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system
por: Rysz, Susanne, et al.
Publicado: (2021)

Effect of renin-angiotensin-aldosterone system inhibitors on Covid-19 patients in Korea
por: Park, Jungchan, et al.
Publicado: (2021)

Relation Between Renin–Angiotensin–Aldosterone System Inhibitors and COVID-19 Severity
por: Alhaddad, Mousa J, et al.
Publicado: (2022)

The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19
por: Mascolo, Annamaria, et al.
Publicado: (2021)

Safety and Efficacy of Renin–Angiotensin–Aldosterone System Inhibitors in COVID-19 Population
por: Sattar, Yasar, et al.
Publicado: (2021)

A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19
por: Sharma, Abhinav, et al.
Publicado: (2022)

Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
por: Golpe, Rafael, et al.
Publicado: (2020)

Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
por: Golpe, Rafael, et al.
Publicado: (2020)

Management of proteinuria: blockade of the renin–angiotensin–aldosterone system
por: Athavale, Akshay, et al.
Publicado: (2020)

Role of the Renin-Angiotensin System and Aldosterone on Cardiometabolic Syndrome
por: Stiefel, P., et al.
Publicado: (2011)

The Renin-Angiotensin-Aldosterone System in Vascular Inflammation and Remodeling
por: Pacurari, Maricica, et al.
Publicado: (2014)

Independent regulation of renin–angiotensin–aldosterone system in the kidney
por: Nishiyama, Akira, et al.
Publicado: (2018)

Interactions of the DASH Diet with the Renin-Angiotensin-Aldosterone System
por: Maris, Stephen A, et al.
Publicado: (2019)

Erratum for The renin‐angiotensin‐aldosterone system and its suppression
Publicado: (2019)

Renal Modulation: The Renin-Angiotensin-Aldosterone System (RAAS)
por: Natarajan, Aruna, et al.
Publicado: (2008)

The Renin–Angiotensin–Aldosterone System and Coronavirus Disease 2019
por: Coto, Eliecer, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_odl6f03rtt29i4lkhjrfrf3ih7